Clinical Trial Update: A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating MK-6070 (HPN328-4001), a DLL3-targeted therapy, in advanced cancers expressing DLL3, including small cell lung cancer and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• MK-6070 (HPN328-4001)

Snippet

Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Small-Cell Lung Cancer, Neuroendocrine Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING